Michael Kozal
Overview
Explore the profile of Michael Kozal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
325
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Petrakis I, Kozal M
Acad Med
. 2022 May;
97(8):1110-1113.
PMID: 35507451
The historic academic affiliation program between the U.S. Department of Veterans Affairs and academic medical centers recently marked its 75th anniversary. The partnership has dramatically influenced medical education, research, and...
2.
Gartland M, Cahn P, DeJesus E, Diaz R, Grossberg R, Kozal M, et al.
Antimicrob Agents Chemother
. 2022 May;
66(6):e0175121.
PMID: 35502922
In the phase 3 BRIGHTE study in heavily treatment-experienced adults with multidrug-resistant HIV-1, fostemsavir plus optimized background therapy (OBT) resulted in sustained rates of virologic suppression through 96 weeks. HIV-1...
3.
Ackerman P, Thompson M, Molina J, Aberg J, Cassetti I, Kozal M, et al.
AIDS
. 2021 May;
35(7):1061-1072.
PMID: 33946085
Objectives: The aim of this study was to understand how demographic and treatment-related factors impact responses to fostemsavir-based regimens. Design: BRIGHTE is an ongoing phase 3 study evaluating twice-daily fostemsavir...
4.
Seval N, Frank C, Kozal M
Expert Rev Anti Infect Ther
. 2020 Dec;
19(8):961-966.
PMID: 33331202
: For those with heavily treatment experienced (HTE) HIV-1 and virologic failure, therapeutic options are limited. A variety of barriers such as drug resistance, side effects, past intolerance, and administration...
5.
Lataillade M, Lalezari J, Kozal M, Aberg J, Pialoux G, Cahn P, et al.
Lancet HIV
. 2020 Oct;
7(11):e740-e751.
PMID: 33128903
Background: Fostemsavir, a prodrug of the first-in-class attachment inhibitor, temsavir, is indicated for heavily treatment-experienced individuals with multidrug-resistant HIV-1. We previously reported superior efficacy of fostemsavir versus placebo in the...
6.
Federman D, Gupta S, Stack G, Campbell S, Peaper D, Dembry L, et al.
PLoS One
. 2020 Aug;
15(8):e0237127.
PMID: 32756602
Background: The global pandemic of Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV2) has resulted in unprecedented challenges for healthcare systems. One barrier to widespread testing has been a paucity of...
7.
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina J, et al.
N Engl J Med
. 2020 Mar;
382(13):1232-1243.
PMID: 32212519
Background: Among some patients with human immunodeficiency virus type 1 (HIV-1) infection who have undergone multiple antiretroviral therapies and have limited options for treatment, new classes of antiretroviral drugs with...
8.
Fuchs M, Monto A, Brau N, Charafeddine M, Schmidt W, Kozal M, et al.
J Med Virol
. 2019 Dec;
92(12):3459-3464.
PMID: 31829433
Hepatitis C virus (HCV) infections are more common among US veterans receiving care through Veterans Affairs (VA) Medical Centers than among the general population. Historically, HCV therapies had lower efficacy...
9.
Helou E, Shenoi S, Kyriakides T, Landry M, Kozal M, Barakat L
J Int Assoc Provid AIDS Care
. 2016 Dec;
16(3):261-266.
PMID: 27903948
Objective: Very-low-level viremia (VLLV) is a relatively new concept in the realm of human immunodeficiency virus (HIV) care. Newer generation assays are now able to detect plasma HIV RNA Viral...
10.
Walker W, Kurscheid S, Joshi S, Lopez C, Goh G, Choi M, et al.
J Virol
. 2015 Mar;
89(10):5502-14.
PMID: 25740989
Unlabelled: Elite controllers (ECs) are a rare group of HIV seropositive individuals who are able to control viral replication without antiretroviral therapy. The mechanisms responsible for this phenotype, however, have...